ZFIN ID: ZDB-FISH-150901-21593
Fish name: TU + MO1-sim1a
Genotype: TU
Targeting Reagent: MO1-sim1a
HUMAN DISEASE MODELED by TU + MO1-sim1a
No data available
GENE EXPRESSION
Gene expression in TU + MO1-sim1a
RNA expression
Expressed Gene Structure Conditions Figures
slc12a1 chemical treatment: all-trans-retinoic acid Fig. 7 S2 with image from Poureetezadi et al., 2016
Fig. 6 with imageFig. 7 with image from Cheng et al., 2015
standard conditions Fig. 7 S2 with image from Poureetezadi et al., 2016
Fig. 3 with imageFig. 6 with imageFig. 7 with imageFig. S6 with image from Cheng et al., 2015
slc12a3 chemical treatment: all-trans-retinoic acid Fig. 7 S2 with image from Poureetezadi et al., 2016
Fig. 6 with imageFig. 7 with image from Cheng et al., 2015
standard conditions Fig. 7 S2 with image from Poureetezadi et al., 2016
Fig. 3 with imageFig. 6 with imageFig. 7 with imageFig. S6 with image from Cheng et al., 2015
slc20a1a chemical treatment: all-trans-retinoic acid Fig. 7 S2 with image from Poureetezadi et al., 2016
Fig. 6 with image from Cheng et al., 2015
standard conditions Fig. 7 S2 with image from Poureetezadi et al., 2016
Fig. 3 with imageFig. 6 with imageFig. S6 with image from Cheng et al., 2015
stc1 chemical treatment: all-trans-retinoic acid Fig. 6 with imageFig. 7 with image from Cheng et al., 2015
standard conditions Fig. 3 with imageFig. 6 with imageFig. 7 with imageFig. S6 with image from Cheng et al., 2015
trpm7 chemical treatment: all-trans-retinoic acid Fig. 7 with image from Poureetezadi et al., 2016
Fig. 6 with image from Cheng et al., 2015
standard conditions Fig. 7 with image from Poureetezadi et al., 2016
Fig. 3 with imageFig. 6 with imageFig. S6 with image from Cheng et al., 2015
Protein expression No data available
Reporter gene expression No data available
PHENOTYPE
Phenotype in TU + MO1-sim1a
Phenotype Conditions Figures
corpuscles of Stannius stc1 expression absent, abnormal standard conditions Fig. 3 with image from Cheng et al., 2015
eye decreased size, abnormal standard conditions Fig. 2 with image from Cheng et al., 2015
head apoptotic, abnormal standard conditions Fig. 2 with image from Cheng et al., 2015
head decreased size, abnormal standard conditions Fig. 2 with image from Cheng et al., 2015
heart edematous, abnormal standard conditions Fig. 2 with image from Cheng et al., 2015
pronephric distal early tubule increased length, abnormal chemical treatment: 4-(diethylamino)benzaldehyde Fig. 7 with image from Cheng et al., 2015
pronephric distal early tubule mislocalised anteriorly, abnormal chemical treatment: 4-(diethylamino)benzaldehyde Fig. 7 with image from Cheng et al., 2015
pronephric distal early tubule mislocalised posteriorly, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from Cheng et al., 2015
pronephric distal early tubule morphology, normal standard conditions Fig. 3 with image from Cheng et al., 2015
pronephric distal early tubule slc12a1 expression spatial pattern, ameliorated chemical treatment by environment: 16,16-dimethylprostaglandin E2 Fig. 7 S2 with image from Poureetezadi et al., 2016
pronephric distal late tubule slc12a3 expression decreased distribution, abnormal control Fig. 7 S2 with image from Poureetezadi et al., 2016
pronephric distal late tubule slc12a3 expression decreased distribution, abnormal chemical treatment by environment: 16,16-dimethylprostaglandin E2 Fig. 7 S2 with image from Poureetezadi et al., 2016
pronephric distal late tubule decreased length, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from Cheng et al., 2015
pronephric distal late tubule increased length, abnormal chemical treatment: 4-(diethylamino)benzaldehyde Fig. 7 with image from Cheng et al., 2015
pronephric distal late tubule morphology, normal standard conditions Fig. 3 with image from Cheng et al., 2015
pronephric nephron tubule development process quality, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from Cheng et al., 2015
pronephric nephron tubule development process quality, abnormal chemical treatment: 4-(diethylamino)benzaldehyde Fig. 7 with image from Cheng et al., 2015
pronephric nephron tubule development process quality, abnormal standard conditions Fig. 6 with imageFig. 7 with image from Cheng et al., 2015
pronephric proximal convoluted tubule distended, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from Cheng et al., 2015
pronephric proximal convoluted tubule distended, abnormal standard conditions Fig. 3 with imageFig. 6 with imageFig. S6 with image from Cheng et al., 2015
pronephric proximal convoluted tubule slc20a1a expression increased distribution, abnormal standard conditions Fig. 7 S2 with image from Poureetezadi et al., 2016
Fig. 3 with image from Cheng et al., 2015
pronephric proximal convoluted tubule slc20a1a expression increased distribution, abnormal chemical treatment by environment: 16,16-dimethylprostaglandin E2 Fig. 7 S2 with image from Poureetezadi et al., 2016
pronephric proximal convoluted tubule slc20a1a expression mislocalised, abnormal standard conditions Fig. 3 with image from Cheng et al., 2015
pronephric proximal convoluted tubule mislocalised posteriorly, abnormal standard conditions Fig. 3 with image from Cheng et al., 2015
pronephric proximal convoluted tubule straight, abnormal standard conditions Fig. 2 with image from Cheng et al., 2015
pronephric proximal straight tubule trpm7 expression absent, abnormal standard conditions Fig. 7 with image from Poureetezadi et al., 2016
Fig. 3 with image from Cheng et al., 2015
pronephric proximal straight tubule absent, abnormal standard conditions Fig. 7 with image from Poureetezadi et al., 2016
pronephric proximal straight tubule absent, abnormal chemical treatment by environment: 16,16-dimethylprostaglandin E2 Fig. 7 with image from Poureetezadi et al., 2016
pronephric proximal straight tubule trpm7 expression absent, abnormal chemical treatment by environment: 16,16-dimethylprostaglandin E2 Fig. 7 with image from Poureetezadi et al., 2016
pronephric proximal straight tubule decreased size, abnormal standard conditions Fig. 3 with imageFig. S6 with image from Cheng et al., 2015
pronephric proximal tubule morphogenesis decreased process quality, abnormal standard conditions Fig. 2 with imageFig. 3 with image from Cheng et al., 2015
pronephric proximal tubule morphogenesis process quality, abnormal standard conditions Fig. 3 with image from Cheng et al., 2015
pronephros lacks all parts of type pronephric proximal straight tubule, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from Cheng et al., 2015
pronephros lacks all parts of type corpuscles of Stannius, abnormal standard conditions Fig. 3 with imageFig. 6 with imageFig. 7 with imageFig. S6 with image from Cheng et al., 2015
pronephros lacks all parts of type pronephric proximal straight tubule, abnormal standard conditions Fig. 6 with image from Cheng et al., 2015
pronephros lacks all parts of type corpuscles of Stannius, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from Cheng et al., 2015
pronephros lacks all parts of type corpuscles of Stannius, abnormal chemical treatment: 4-(diethylamino)benzaldehyde Fig. 7 with image from Cheng et al., 2015
renal filtration decreased process quality, abnormal standard conditions Fig. 2 with image from Cheng et al., 2015

CITATIONS  (3)